Table 1.
Demographic and clinical variables, mean (standard deviation)
| HC (N = 31) | AD (N = 29) | DLB (N = 31) | Between‐group differences | |
|---|---|---|---|---|
| Male:Female | 22:9 | 20:9 | 19:12 | χ2 = 0.73, p = 0.70a |
| Study 1:Study 2 | 15:16 | 13:16 | 12:19 | χ2 = 0.60, p = 0.74a |
| Age | 76.4 (7.2) | 75.2 (8.6) | 78.13 (6.7) | F2,88 = 1.16, p = 0.32b |
| AChEI | ‐ | 26 | 28 | χ2 = 0.007, p = 0.93c |
| PD meds | ‐ | 1 | 18 | χ2 = 20.66, p < 0.001c |
| Duration | ‐ | 3.7 (1.7)f | 3.4 (2.3) | U = 339, p = 0.14d |
| MMSE | 28.9 (1.1) | 21.8 (3.8) | 22.03 (4.3) | t58 = 0.20, p = 0.85e |
| CAMCOG | 96.7 (3.2) | 70.3 (13.5) | 73.29 (13.6) | t58 = 0.86, p = 0.39e |
| UPDRS III | 1.94 (2.8) | 3.5 (4.0) | 18.1 (10.2) | t58 = 7.32, p < 0.001e |
| CAF total | ‐ | 1.00 (2.51)f | 4.8 (4.9)g | t56 = 3.66, p = 0.001e |
| NPI total | ‐ | 5.9 (5.5)h | 14.55 (11.03)i | t54 = 3.68, p = 0.001e |
| NPI hall | ‐ | 0j | 1.6 (1.8)i | t53 = 4.53, p < 0.001e |
Note. AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer's disease; CAF total, Clinical Assessment of Fluctuations total score; CAMCOG, Cambridge Cognitive Examination; DLB, dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; Mayo total, Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale; Mayo arousal, Mayo Fluctuations arousal subscale; MMSE, Mini Mental State Examination; PD meds, number of patients taking dopaminergic medication for the management of Parkinson's disease symptoms; UPDRS III, Unified Parkinson's Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore.
Chi‐square test HC, AD, DLB.
One‐way ANOVA HC, AD, DLB.
Chi‐square test AD, DLB.
Mann–Whitney U test AD, DLB.
Student's t‐ test AD, DLB.
N = 28.
N = 30.
N = 27.
N = 29.
N = 26.